Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
American Journal of Surgery|January 11, 2003
Management of patients with severe sepsis, treated by drotrecogin alfa (activated)Pierre-François Laterre, Darell HeiselmanThe Journal of Sexual Medicine|November 8, 2017
Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims StudyHu Li, Lucy Mitchell, Xiang Zhang, et al.The Journal of Urology|April 28, 2016
9-Month Efficacy and Safety Study of Testosterone Solution 2% for Sex Drive and Energy in Hypogonadal MenGerald Brock, Darell Heiselman, Jack Knorr, et al.The Journal of Sexual Medicine|July 21, 2016
Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal MenMario Maggi, Darell Heiselman, Jack Knorr, et al.The Journal of Sexual Medicine|June 23, 2016
Demographic and Clinical Correlates of Patient-Reported Improvement in Sex Drive, Erectile Function, and Energy With Testosterone Solution 2Frederick Wu, Michael Zitzmann, Darell Heiselman, et al.BMC Research Notes|July 4, 2012
Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysisEric S Meadows, Jay P Bae, Anthony Zagar, et al.Journal of Critical Care|February 13, 2010
Troponin-I as a prognosticator of mortality in severe sepsis patientsJijo John, D Bradley Woodward, Yanping Wang, et al.The Journal of Urology|October 27, 2015
Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled StudyGerald Brock, Darell Heiselman, Mario Maggi, et al.Critical Care (London, England)|December 24, 2010
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)Andrew F Shorr, Jonathan M Janes, Antonio Artigas, et al.Journal of Pediatric Hematology/Oncology|December 11, 2014
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging studyLori Styles, Darell Heiselman, Lori E Heath, et al.Pageof 2